A Phase 1/2 clinical trial Opdivo (nivolumab) and NKTR-214 combination in melanoma, kidney, colorectal, bladder and non-small cell lung cancer patients.

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 10 Oct 2016

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Bempegaldesleukin (Primary) ; Nivolumab (Primary)
Indications Bladder cancer; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Renal cancer
Focus Adverse reactions; Therapeutic Use

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com